文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging.

作者信息

Jadvar Hossein, Calais Jeremie, Fanti Stefano, Feng Felix, Greene Kirsten L, Gulley James L, Hofman Michael, Koontz Bridget F, Lin Daniel W, Morris Michael J, Rowe Steve P, Royce Trevor J, Salami Simpa, Savir-Baruch Bital, Srinivas Sandy, Hope Thomas A

机构信息

Department of Radiology, University of Southern California, Los Angeles, California;

Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California.

出版信息

J Nucl Med. 2022 Jan;63(1):59-68. doi: 10.2967/jnumed.121.263262. Epub 2021 Sep 30.

DOI:10.2967/jnumed.121.263262
PMID:34593595
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8717184/
Abstract
摘要

相似文献

[1]
Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging.

J Nucl Med. 2022-1

[2]
Writing PET into existence.

Eur J Nucl Med Mol Imaging. 2014-1

[3]
Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls.

Semin Nucl Med. 2019-3-4

[4]
The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer.

Asian J Androl. 2021

[5]
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.

Eur Urol Oncol. 2018-5-15

[6]
Will GRPR Compete with PSMA as a Target in Prostate Cancer?

J Nucl Med. 2017-12

[7]
Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.

Eur Urol Focus. 2016-11-15

[8]
Prostate-Specific Membrane Antigen: The Target of the Decade, from Biochemical Recurrence to Widespread Adoption.

J Nucl Med. 2020-12

[9]
68Ga-Prostate-Specific Membrane Antigen-Avid Tubercular Lesions Mimicking Prostate Cancer Metastasis on Simultaneous Prostate-Specific Membrane Antigen PET/MRI.

Clin Nucl Med. 2017-12

[10]
PSMA-negative prostate cancer and the continued value of choline-PET/CT.

Nuklearmedizin. 2020-2

引用本文的文献

[1]
A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer.

EJNMMI Res. 2025-7-24

[2]
Pharmacokinetics and dosimetry of [Lu]Lu-PSMA-617 and [Ga]Ga-PSMA-11 in Japanese patients with PSMA-positive mCRPC.

Ann Nucl Med. 2025-7-10

[3]
The impact of patient hydration and forced diuresis on [F]PSMA-1007 urinary bladder uptake in PET/CT imaging.

EJNMMI Res. 2025-6-19

[4]
Semiquantitative Analysis in PET/CT Imaging of Prostate Cancer.

J Clin Med. 2025-5-29

[5]
Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) in Initial Staging of Prostate Cancer Patients: The Beginning of a New Era.

Medicina (Kaunas). 2025-5-20

[6]
PSMA PET Imaging in the Management of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radioligand Therapy.

Target Oncol. 2025-5-26

[7]
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer.

Oncologist. 2025-5-8

[8]
The evolving role of positron emission tomography in precision prostate cancer biopsy.

Eur J Clin Invest. 2025-8

[9]
MDT perspective: innovative applications of stereotactic body radiation therapy in metastatic castration-resistant prostate cancer.

Prostate Cancer Prostatic Dis. 2024-11-18

[10]
Update on PSMA-based Prostate Cancer Imaging.

Semin Nucl Med. 2024-11

本文引用的文献

[1]
Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial.

JAMA Oncol. 2021-11-1

[2]
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

N Engl J Med. 2021-9-16

[3]
F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.

Lancet. 2021-5-22

[4]
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with F-DCFPyL in Prostate Cancer Patients (OSPREY).

J Urol. 2021-7

[5]
Diagnostic Performance of F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study.

Clin Cancer Res. 2021-7-1

[6]
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET.

Eur J Nucl Med Mol Imaging. 2021-5

[7]
Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.

JAMA Oncol. 2021-4-1

[8]
[Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.

Lancet. 2021-2-27

[9]
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.

J Natl Compr Canc Netw. 2021-2-2

[10]
Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study.

J Urol. 2021-6

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索